Nanjing Shuohui Pharmaceutical Technology Co., Ltd.

Using lansoprazole enteric-coated capsules as a control, the efficacy and safety of different dosage regimens of XC2309 tablets in the treatment of duodenal ulcer were explored.

To evaluate the safety, tolerability, and pharmacokinetic characteristics of XC2309 tablets after single and multiple administration in healthy subjects; to evaluate the pharmacokinetic characteristics of XC2309 tablets in healthy subjects in the fasting and postprandial states, and to evaluate the effect of food on the pharmacokinetic characteristics; to evaluate the pharmacodynamic characteristics of XC2309 tablets after single and multiple administration in healthy subjects, and to provide a basis for dose selection in later clinical studies; to explore and identify the main metabolites in the human body after a single administration of XC2309 tablets in healthy subjects.